Abstract：
OBJECTIVE: The COVID-19 pandemic has had a profound impact on individuals with mental health (MH) disorders and on the delivery of MH services. Studies examining treatment models which did not require substantial changes to the delivery of services during pandemic restrictions, such as collaborative care management (CoCM) programs are minimal. Therefore, a longitudinal retrospective cohort analysis was conducted to examine the impacts of the COVID-19 pandemic on a psychopharmacological CoCM program.
METHODS: Data was collected on all U.S. Veterans enrolled in a CoCM program at a large VA during the first 10 months of the COVID-19 pandemic and compared to a one-year prior date matched control group. Treatment in the program pre-COVID vs. treatment during the pandemic was compared in relation to baseline symptomatology, improvements in MH symptoms, and program adherence.
RESULTS: 462 Veterans were referred during the control dates, compared to 351 during the pandemic. Veterans enrolled during the first four months of each study arm, done to allow for a minimum of 6 months of follow up data, had no differences in baseline symptoms of depression or anxiety. Veterans receiving care during the pandemic had higher rates of program completion than pre-pandemic controls. COVID-era Veterans had higher rates of depression response than controls, and no differences were observed in depression remission, anxiety response, or anxiety remission.
CONCLUSIONS: Psychopharmacological CoCM treatment models can successfully manage depression and anxiety with no observed decrease in the effectiveness of this intervention even during periods of unprecedented disruptions to the delivery of MH services.
METHODS: Data was collected on all U.S. Veterans enrolled in a CoCM program at a large VA during the first 10 months of the COVID-19 pandemic and compared to a one-year prior date matched control group. Treatment in the program pre-COVID vs. treatment during the pandemic was compared in relation to baseline symptomatology, improvements in MH symptoms, and program adherence.
RESULTS: 462 Veterans were referred during the control dates, compared to 351 during the pandemic. Veterans enrolled during the first four months of each study arm, done to allow for a minimum of 6 months of follow up data, had no differences in baseline symptoms of depression or anxiety. Veterans receiving care during the pandemic had higher rates of program completion than pre-pandemic controls. COVID-era Veterans had higher rates of depression response than controls, and no differences were observed in depression remission, anxiety response, or anxiety remission.
CONCLUSIONS: Psychopharmacological CoCM treatment models can successfully manage depression and anxiety with no observed decrease in the effectiveness of this intervention even during periods of unprecedented disruptions to the delivery of MH services.
摘要：
目标：COVID-19大流行对精神健康(MH)障碍患者和MH服务的提供产生了深远的影响。研究检查治疗模式，这些模式在大流行限制期间不需要对服务的提供进行重大改变，例如协作护理管理(CoCM)计划是最小的。因此,我们进行了一项纵向回顾性队列分析,以研究COVID-19大流行对精神药理学CoCM计划的影响.
方法：在COVID-19大流行的前10个月，收集了在大型VA中参加CoCM计划的所有美国退伍军人的数据，并与一年前匹配的对照组进行了比较。方案中的治疗前COVID与大流行期间的治疗与基线症状学进行了比较，改善MH症状，和程序坚持。
结果：462名退伍军人在控制日期期间被转诊，与大流行期间的351相比。退伍军人在每个研究小组的前四个月注册，允许至少6个月的随访数据，在抑郁或焦虑的基线症状方面没有差异。在大流行期间接受护理的退伍军人的计划完成率高于大流行前的控制措施。COVID时代退伍军人的抑郁反应率高于对照组，在抑郁缓解方面没有观察到差异，焦虑反应，或焦虑缓解。
结论：精神药理学CoCM治疗模式可以成功治疗抑郁和焦虑，即使在MH服务的提供出现前所未有的中断期间，这种干预措施的有效性也没有下降。
方法：在COVID-19大流行的前10个月，收集了在大型VA中参加CoCM计划的所有美国退伍军人的数据，并与一年前匹配的对照组进行了比较。方案中的治疗前COVID与大流行期间的治疗与基线症状学进行了比较，改善MH症状，和程序坚持。
结果：462名退伍军人在控制日期期间被转诊，与大流行期间的351相比。退伍军人在每个研究小组的前四个月注册，允许至少6个月的随访数据，在抑郁或焦虑的基线症状方面没有差异。在大流行期间接受护理的退伍军人的计划完成率高于大流行前的控制措施。COVID时代退伍军人的抑郁反应率高于对照组，在抑郁缓解方面没有观察到差异，焦虑反应，或焦虑缓解。
结论：精神药理学CoCM治疗模式可以成功治疗抑郁和焦虑，即使在MH服务的提供出现前所未有的中断期间，这种干预措施的有效性也没有下降。
